1001350-96-4 | BMS-754807

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$51.00	$36.00
5mg	98%	in stock	$114.00	$80.00
10mg	98%	in stock	$172.00	$120.00
25mg	98%	in stock	$256.00	$179.00
50mg	98%	in stock	$434.00	$304.00

Description

• Catalog Number: AE11157
• Chemical Name: BMS-754807
• CAS Number: 1001350-96-4
• Molecular Formula: C23H24FN9O
• Molecular Weight: 461.4948
• MDL Number: MFCD18633202
• SMILES: Fc1ccc(cn1)NC(=O)[C@]1(C)CCCN1c1nc(Nc2n[nH]c(c2)C2CC2)c2n(n1)ccc2

Computed Properties

• Complexity: 756
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 34
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 6
• XLogP3: 2.9

Upstream Synthesis Route

BMS-754807, a potent small molecule inhibitor, is widely utilized in chemical synthesis as a crucial tool for the modulation of various biological processes. Its ability to selectively target specific protein kinases makes it a valuable asset in designing and developing new compounds for pharmaceutical purposes. In chemical synthesis, BMS-754807 is instrumental in enabling researchers to manipulate signaling pathways and study the intricate mechanisms underlying cellular functions. By incorporating BMS-754807 into reaction mixtures, chemists can facilitate the production of novel compounds with enhanced properties, paving the way for innovative drug discovery and development.

Literature

• CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.

  Cancer research 20140715

• Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors.

  Pancreas 20130401

• IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein.

  Experimental hematology 20120901

• Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.

  Cancer research 20111215

• High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110415

• Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.

  Endocrine-related cancer 20100901

• Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase.

  Bioorganic & medicinal chemistry letters 20100901

• LC-MS/MS method using unbonded silica column and aqueous/methanol mobile phase for the simultaneous quantification of a drug candidate and co-administered metformin in rat plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100601

• Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.

  Journal of medicinal chemistry 20091210

• BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

  Molecular cancer therapeutics 20091201